Novo Nordisk successfully completes diabetes drug phase 3a trial

Client Viola Sanon has her finger pricked for a blood sugar test in the Family Van in Boston, Massachusetts, August 9, 2010. Every week, dozens of residents of this low-income Boston neighborhood stop into the Family Van, an RV manned by healthcare workers affiliated with Harvard Medical School who perform simple, free screenings, including blood pressure, body mass index and blood sugar, which can alert patients if they face an elevated risk for diabetes, hypertension or other chronic conditions. REUTERS/Brian Snyder (UNITED STATES - Tags: HEALTH SOCIETY)
(Reuters)

COPENHAGEN – Danish pharmaceutical company Novo Nordisk has successfully completed the second phase 3a trial with its diabetes drug semaglutide, it said on Friday.

"We are excited about these trial results, which show that 1.0 mg semaglutide injected once weekly provided better glycaemic control and greater weight loss than 2.0 mg exenatideonce-weekly," chief science officer Mads Krogsgaard Thomsen said in a statement.

Novo Nordisk said semaglutide appeared to have a safe and well-tolerated profile.